» Articles » PMID: 8653891

Ultrasensitive Detection of Prostate-specific Antigen by a Time-resolved Immunofluorometric Assay and the Immulite Immunochemiluminescent Third-generation Assay: Potential Applications in Prostate and Breast Cancers

Overview
Journal Clin Chem
Specialty Biochemistry
Date 1996 May 1
PMID 8653891
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

We report an ultrasensitive time-resolved immunofluorometric assay (TRIFA) for prostate-specific antigen (PSA). The assay is an improvement of our previous report (Clin Chem 1993;39:2108-14) and includes the utilization of two monoclonal antibodies and a one-step incubation period, which greatly reduces analysis time. The new method demonstrates a superior lower analytical limit of detection (< or = 1 ng/L), a wide dynamic range, absence of a hook effect at 10(6) ng/L PSA, and equimolarity for free PSA and PSA-antichymotrypsin complex. Also, we have compared several aspects of our TRIFA with a commercially available third-generation assay (Immulite). An evaluation of breast tumor cytosol extracts from 315 patients shows PSA immunoreactivity > 15 ng/g of total protein in 28% and 23% by TRIFA and Immulite analysis, respectively. Both methods demonstrate a significant association between breast tumor PSA immunoreactivity and progesterone and estrogen receptor positivity (P <0.001). Analysis of serum samples obtained for monitoring of postradical prostatectomy patients reveals significant PSA changes at concentrations undetectable by conventional methods. The significance of these results as well as the potential applications of ultrasensitive PSA assays in breast and prostate cancers are discussed.

Citing Articles

The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy.

Seikkula H, Hyysalo J, Hogerman M, Bostrom P, Ettala O BJUI Compass. 2024; 5(11):1106-1113.

PMID: 39539557 PMC: 11557256. DOI: 10.1002/bco2.413.


Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review.

von Eyben F, Kairemo K, Kapp D Biomedicines. 2024; 12(4).

PMID: 38672176 PMC: 11048591. DOI: 10.3390/biomedicines12040822.


Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women.

Eklund E, Diamandis E, Muytjens C, Wheeler S, Mathew A, Stengelin M F1000Res. 2017; 6:1131.

PMID: 28815018 PMC: 5539849. DOI: 10.12688/f1000research.11821.1.


Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS).

Diamandis E, Stanczyk F, Wheeler S, Mathew A, Stengelin M, Nikolenko G Clin Chem Lab Med. 2017; 55(11):1789-1797.

PMID: 28361781 PMC: 5742006. DOI: 10.1515/cclm-2016-1124.


Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala T, Seikkula H, Seyednasrollah F, Mirtti T, Bostrom P, Elo L Sci Rep. 2016; 6:36161.

PMID: 27805011 PMC: 5090356. DOI: 10.1038/srep36161.